Cochrane Db Syst Rev
-
Cochrane Db Syst Rev · May 2016
Review Meta AnalysisWITHDRAWN: Puerarin injection for unstable angina pectoris.
The Editor/CRG withdrew this review as the current author team is unable to progress to the final stage of the review update. The editors consider this title as low priority for the current portfolio of the Heart Group and therefore this title is not open to a new author team. The editorial group responsible for this previously published document have withdrawn it from publication.
-
Cochrane Db Syst Rev · May 2016
Review Meta AnalysisWITHDRAWN: Herbal medicines for viral myocarditis.
The editors of Cochrane Heart consider this title as low priority for the current portfolio of the Heart Group and therefore this title is not open to a new author team. The editorial group responsible for this previously published document have withdrawn it from publication.
-
Cochrane Db Syst Rev · May 2016
Review Meta AnalysisAlpha₂-adrenergic agonists for the management of opioid withdrawal.
Withdrawal is a necessary step prior to drug-free treatment or as the endpoint of long-term substitution treatment. ⋯ Clonidine and lofexidine are more effective than placebo for the management of withdrawal from heroin or methadone. We detected no significant difference in efficacy between treatment regimens based on clonidine or lofexidine and those based on reducing doses of methadone over a period of around 10 days, but methadone was associated with fewer adverse effects than clonidine, and lofexidine has a better safety profile than clonidine.
-
Cochrane Db Syst Rev · May 2016
Review Meta AnalysisBlood biomarkers for the non-invasive diagnosis of endometriosis.
About 10% of reproductive-aged women suffer from endometriosis, a costly chronic disease causing pelvic pain and subfertility. Laparoscopy is the gold standard diagnostic test for endometriosis, but is expensive and carries surgical risks. Currently, there are no non-invasive or minimally invasive tests available in clinical practice to accurately diagnose endometriosis. Although other reviews have assessed the ability of blood tests to diagnose endometriosis, this is the first review to use Cochrane methods, providing an update on the rapidly expanding literature in this field. ⋯ Of the biomarkers that were subjected to meta-analysis, none consistently met the criteria for a replacement or triage diagnostic test. A subset of blood biomarkers could prove useful either for detecting pelvic endometriosis or for differentiating ovarian endometrioma from other benign ovarian masses, but there was insufficient evidence to draw meaningful conclusions. Overall, none of the biomarkers displayed enough accuracy to be used clinically outside a research setting. We also identified blood biomarkers that demonstrated no diagnostic value in endometriosis and recommend focusing research resources on evaluating other more clinically useful biomarkers.